|

PD-L1/IDO Peptide Vaccine Clinical Trials

1 actively recruiting trial across 1 location

Also known as: IO102-IO103 Peptide Vaccine, IO103/IO102 Peptide Vaccine, PD-L1/IDO Peptide

Pipeline

Phase 1: 1

Top Sponsors

  • University of California, Davis1

Indications

  • High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma1
  • Stage 0is Bladder Cancer AJCC v81
  • Stage 0a Bladder Cancer AJCC v81
  • Stage I Bladder Cancer AJCC v81
  • Cancer1

Sacramento, California1 trial

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

University of California Davis Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.